Premium
Combined androgen and antimetabolite therapy of advanced female breast cancer A report of the cooperative breast cancer group
Author(s) -
Goldenberg Ira S.,
Sedransk Nell,
Volk Herbert,
Segaloff Albert,
Kelley Rita M.,
Haines Carleton R.
Publication year - 1975
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197508)36:2<308::aid-cncr2820360203>3.0.co;2-1
Subject(s) - antimetabolite , medicine , breast cancer , androgen , oncology , randomized controlled trial , cancer , clinical trial , surgery , gynecology , hormone
A clinical trial of androgen and antimetabolite therapy of advanced female breast cancer was conducted in 110 patients by the Cooperative Breast Cancer Group. An objective regression rate of 20% was achieved in women receiving oral testolactone, 6% in patients given intravenous fluorouracil alone, and 14% when the androgen and antimetabolite were administered together. This randomized trial according to the CBCG protocol did not produce the high regression rate noted previously in a nonrandomized, nonprotocol evaluation of these drugs.